New European guidelines issued in August 2026 by the European Society of Cardiology and the European Renal Association establish a unified approach to managing cardiovascular disease and chronic kidney disease together. According to the European Society of Cardiology, approximately 100 million people across Europe live with chronic kidney disease, facing significantly heightened risks of cardiovascular diseases and premature dialysis when both conditions interact.
The Dangerous Interconnection of Heart and Kidney Disease
Heart disease and chronic kidney disease often fuel each other in a destructive clinical feedback loop. Healthy kidneys regulate blood pressure, fluid balance, and several metabolic processes, while the cardiovascular system ensures the steady blood flow necessary for normal kidney performance. When kidney function declines, cardiovascular risk can rise substantially. Conversely, disorders like heart failure reduce blood flow to the kidneys, driving further organ deterioration.
According to Task Force Chair Associate Professor Kevin Damman from University Medical Centre Groningen in the Netherlands, chronic kidney disease can accelerate cardiovascular disease and vice versa. This interaction frequently leads to cardiovascular events and the need for dialysis much earlier in life. The conditions share deep biological ties, meaning that treating them in isolation leaves patients exposed to preventable complications.
The STAMP on CKD Strategy
To streamline clinical practice, the task force introduced the ‘STAMP on CKD’ framework, designed to organize patient care into five distinct priorities: Screen, Triage, Address CKD Risk, Modify CVD management, and Plan health services. Published in the European Heart Journal and presented at the ESC Congress 2026, the guidelines urge clinicians to move past traditional boundaries separating cardiology and nephrology.
Screening forms the foundational first step of the framework. According to Task Force Chair Professor William Herrington from the University of Oxford, many patients with chronic kidney disease are managed primarily by the cardiology community. The new guidelines aim to increase routine kidney function and urine albumin testing in patients diagnosed with cardiovascular disease. Specifically, clinicians should utilize blood creatinine tests to calculate the estimated glomerular filtration rate and urine tests to measure the albumin-to-creatinine ratio.
Early Interventions and Coordinated Care
Once clinicians identify kidney abnormalities through screening, triage tools evaluate a patient’s risk of progressing to kidney failure alongside their overall cardiovascular risk. Early detection opens a critical window for intervention. According to Associate Professor Damman, introducing specific therapies early can substantially slow the progression of kidney disease and lower the likelihood of adverse cardiovascular events.
The guidelines highlight several evidence-based treatments, including renin-angiotensin system inhibitors and SGLT2 inhibitors, alongside statin-based therapy. For patients with chronic kidney disease, type 2 diabetes, and albuminuria, the recommendations also point to finerenone and GLP-1 receptor agonists such as semaglutide as options to reduce kidney and cardiovascular risks. Because reduced kidney function alters how the body clears medications, the guidelines provide explicit guidance on adjusting treatments safely.
Effective management ultimately requires structured collaboration between specialists. Professor Herrington notes that active and efficient communication between specialties is essential for navigating complex patient profiles. By engaging patients and caregivers in this multidisciplinary process, healthcare providers can better align treatments with individual priorities and improve the patient experience.
Related reading